Hyperrho
HyperRho® S/D
Product Specs | HyperRho® S/D |
---|---|
Manufacturer Name | Grifols |
Indications | Mini-Dose For prevention of isoimmunization in Rho(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks’ gestation. Full Dose |
Contraindications | None known. Rho(D) Immune Globin (Human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations |
Viral Safety Process | Precipitation, depth filtration, solvent/detergent treatment. The final container incubation step used during the manufacture of HyperRho S/D contributes to virus inactivation. |
Route of Administration | Intramuscular |
Clearance of Rh-positive Red Blood Cells | Mini-Dose Each single dose syringe contains sufficient anti-Rho(D) to effectively suppress the immunizing potential of 2.5 mL of Rho(D) positive packed red blood cells or the equivalent of whole blood (5 mL). Full Dose |
Product Half-Life | Approx. 23-26 days |
Latex Content | HyperRhO S/D mini-dose and HyperRho S/D full dose prefilled disposable syringes in a latex-free delivery system. |
Thimerosal Content | No |
Storage Requirements |
|
Shelf Life | 36 months from manufactured date |
Supply Method | Preservative (thimerosol)-free, prefilled disposable syringes with attached UltraSafe Needle Guard in a latex-free delivery system |
Available Sizes | Mini-Dose: 250 IU prefilled disposable syringe in 10pk Full Dose: 1500 IU prefilled disposable syringe in 10pk and single syringe |
Return to Manufacturer Name listing Return to Factor Type listing